Vivesto AB (VIVE.ST)
SEK 0.27
(-1.45%)
SEK 0.27
(-1.45%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2022 | 1.01 Million SEK | -96.12% |
| 2021 | 26.19 Million SEK | -87.02% |
| 2020 | 201.84 Million SEK | 0.0% |
| 2019 | 201.84 Million SEK | 10094.09% |
| 2018 | 1.98 Million SEK | -37.52% |
| 2017 | 3.16 Million SEK | 1742.44% |
| 2016 | 172 Thousand SEK | -97.3% |
| 2015 | 6.37 Million SEK | 207.87% |
| 2014 | 2.07 Million SEK | 3350.0% |
| 2013 | 60 Thousand SEK | 0.0% |
| 2012 | - SEK | -100.0% |
| 2011 | 891 Thousand SEK | 740.57% |
| 2010 | 106 Thousand SEK | -99.66% |
| 2009 | 30.74 Million SEK | -61.26% |
| 2008 | 79.35 Million SEK | 11.52% |
| 2007 | 71.15 Million SEK | 217.85% |
| 2006 | 22.38 Million SEK | 2523.82% |
| 2005 | 853.22 Thousand SEK | 7756463.64% |
| 2004 | 11.00 SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 Q1 | - SEK | 0.0% |
| 2023 Q2 | - SEK | 0.0% |
| 2022 Q3 | 1.01 Million SEK | 0.0% |
| 2022 FY | 1.01 Million SEK | -96.12% |
| 2022 Q1 | - SEK | -100.0% |
| 2022 Q2 | - SEK | 0.0% |
| 2022 Q4 | - SEK | -100.0% |
| 2021 Q1 | 37 Thousand SEK | 100.02% |
| 2021 Q4 | 9.63 Million SEK | -19.14% |
| 2021 Q2 | 4.59 Million SEK | 12321.62% |
| 2021 Q3 | 11.92 Million SEK | 159.36% |
| 2021 FY | 26.19 Million SEK | -87.02% |
| 2020 Q1 | 201.26 Million SEK | 139668.06% |
| 2020 Q2 | 208 Thousand SEK | -99.9% |
| 2020 Q3 | 154 Thousand SEK | -25.96% |
| 2020 Q4 | -200.15 Million SEK | -130070.78% |
| 2020 FY | 201.84 Million SEK | 0.0% |
| 2019 Q1 | 266 Thousand SEK | -81.36% |
| 2019 Q4 | 144 Thousand SEK | -42.86% |
| 2019 FY | 201.84 Million SEK | 10094.09% |
| 2019 Q3 | 252 Thousand SEK | 38.46% |
| 2019 Q2 | 182 Thousand SEK | -31.58% |
| 2018 Q2 | 128 Thousand SEK | -84.82% |
| 2018 FY | 1.98 Million SEK | -37.52% |
| 2018 Q4 | 1.42 Million SEK | 803.16% |
| 2018 Q1 | 843 Thousand SEK | 28.51% |
| 2018 Q3 | 158 Thousand SEK | 23.44% |
| 2017 Q2 | 20 Thousand SEK | -54.55% |
| 2017 Q4 | 656 Thousand SEK | -60.27% |
| 2017 FY | 3.16 Million SEK | 1742.44% |
| 2017 Q3 | 1.65 Million SEK | 8155.0% |
| 2017 Q1 | 44 Thousand SEK | 22.22% |
| 2016 FY | 172 Thousand SEK | -97.3% |
| 2016 Q1 | 58 Thousand SEK | -99.04% |
| 2016 Q4 | 36 Thousand SEK | -35.71% |
| 2016 Q3 | 56 Thousand SEK | 55.56% |
| 2016 Q2 | 36 Thousand SEK | -37.93% |
| 2015 Q1 | 36 Thousand SEK | -92.53% |
| 2015 Q4 | 6.04 Million SEK | 11521.15% |
| 2015 Q2 | 219 Thousand SEK | 508.33% |
| 2015 Q3 | 52 Thousand SEK | -76.26% |
| 2015 FY | 6.37 Million SEK | 207.87% |
| 2014 Q2 | 994 Thousand SEK | 4870.0% |
| 2014 Q3 | 558 Thousand SEK | -43.86% |
| 2014 Q4 | 482 Thousand SEK | -13.62% |
| 2014 Q1 | 20 Thousand SEK | 25.0% |
| 2014 FY | 2.07 Million SEK | 3350.0% |
| 2013 Q4 | 16 Thousand SEK | -33.33% |
| 2013 Q3 | 24 Thousand SEK | 0.0% |
| 2013 Q2 | - SEK | 0.0% |
| 2013 Q1 | - SEK | 0.0% |
| 2013 FY | 60 Thousand SEK | 0.0% |
| 2012 Q3 | - SEK | 0.0% |
| 2012 Q4 | - SEK | 0.0% |
| 2012 FY | - SEK | -100.0% |
| 2012 Q1 | - SEK | 0.0% |
| 2012 Q2 | - SEK | 0.0% |
| 2011 Q4 | - SEK | 0.0% |
| 2011 FY | 891 Thousand SEK | 740.57% |
| 2011 Q1 | - SEK | -100.0% |
| 2011 Q2 | 891 Thousand SEK | 0.0% |
| 2011 Q3 | - SEK | -100.0% |
| 2010 Q2 | 42 Thousand SEK | -99.24% |
| 2010 Q3 | - SEK | -100.0% |
| 2010 Q4 | 64 Thousand SEK | 0.0% |
| 2010 FY | 106 Thousand SEK | -99.66% |
| 2010 Q1 | 5.5 Million SEK | 1588.65% |
| 2009 Q4 | 326 Thousand SEK | 28.85% |
| 2009 Q2 | 24.65 Million SEK | 0.0% |
| 2009 Q3 | 253 Thousand SEK | -98.97% |
| 2009 FY | 30.74 Million SEK | -61.26% |
| 2008 FY | 79.35 Million SEK | 11.52% |
| 2007 FY | 71.15 Million SEK | 217.85% |
| 2006 FY | 22.38 Million SEK | 2523.82% |
| 2005 FY | 853.22 Thousand SEK | 7756463.64% |
| 2004 FY | 11.00 SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| AcuCort AB | - SEK | -Infinity% |
| AlzeCure Pharma AB (publ) | - SEK | -Infinity% |
| BioGaia AB (publ) | 1.29 Billion SEK | 99.922% |
| Enzymatica AB (publ) | 50.9 Million SEK | 98.006% |
| Enorama Pharma AB (publ) | 1.35 Million SEK | 25.258% |
| Gabather AB (publ) | - SEK | -Infinity% |
| Klaria Pharma Holding AB (publ.) | - SEK | -Infinity% |
| Moberg Pharma AB (publ) | - SEK | -Infinity% |
| Nanexa AB (publ) | 29.32 Million SEK | 96.539% |
| Newbury Pharmaceuticals AB (publ) | 36.82 Million SEK | 97.244% |
| ODI Pharma AB | 22.44 Million SEK | 95.478% |
| Orexo AB (publ) | 638.8 Million SEK | 99.841% |
| Probi AB (publ) | 627.68 Million SEK | 99.838% |
| Swedencare AB (publ) | 2.32 Billion SEK | 99.956% |
| Swedish Orphan Biovitrum AB (publ) | 22.12 Billion SEK | 99.995% |
| Toleranzia AB | 50.92 Million SEK | 98.007% |